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Purpose: The purpose was to determine the early and late mortality and morbidity rates 
associated with infrainguinal arterial prosthetic graft infection (IAPGI) and to identify 
optimal methods of management. 
Methods: The study included 53 men and 14 women (mean age, 61 years) in whom a total 
of 68 IAPGIs developed in the years 1959 to 1993. IAPGI involved 58 femoropopliteal 
grafts (85 %), six femorodistal grafts (9%), and four other grafts or synthetic patches (6%). 
Graft material was dacron in 36 (53%), polytetrafluoroethylene in 28 (41%), and human 
umbilical vein in four (6%). Sixteen IAPGIs (24%) involved limbs that had required 
amputations before IAPGI was diagnosed. Twenty-six (38%) of the 68 grafts were 
thrombosed, and 14 (88%) of the 16 amputees had occluded grafts. 
Results: Staphylococcal organisms were isolated from 34 (58%) of the 59 IAPGIs for 
which culture data were available. The median intervals until IAPGI was diagnosed were 
3 months after implantation and 1 month after the last procedure involving the original 
graft. Initial management consisted of local measures only in 13 (19%), partial removal 
or in situ graft replacement in 15 (22%), and total graft excision in 40 (59%). Total 
excision was performed in 15 (94%) of the 16 patients with prior amputations and in only 
25 (48%) of the 52 intact limbs. The overall postoperative mortality rate was 18%; seven 
(58%) of the 12 early deaths were related to sepsis, and all 12 occurred within the group 
of 51 patients (24%) for whom limb salvage was still being attempted (20 = 0.056). IAPGI 
ultimately led to amputations in 21 (40%) of 52 intact limbs within the first year. 
Twenty-three (82%) of the 28 IAPGIs managed with incomplete graft removal required 
subsequent operations for continued sepsis, compared with five (13%) of the 40 treated 
with complete xcision (p < 0.001). The cumulative 5-year survival rate (77%) for 53 
patients who survived operation was less than that (89%) for the normal, age-matched 
U.S. male population. 
Conclusions: IAPGI is associated with substantial early mortality and amputation rates. 
Complete excision of infected graft material results in a significant reduction in the 
incidence of recurrent sepsis. (J VASC SURG 1995;21:782-91.) 
One of  the most serious complications associated 
with the use of prosthetic material for vascular 
reconstruction is infection involving the synthetic 
graft. The reported incidence ofinfrainguinal rterial 
From the Department of Vascular Surgery, Cleveland Clinic 
Foundation, Cleveland. 
Presented atthe Eighteenth Annual Meeting of the Midwestern 
Vascular Surgical Society, Cincinnati, Ohio, Sept. 23-24, 1994. 
Reprint requests: Patrick J. O'Hara, MD, Department of Vascular 
Surgery, Cleveland Clinic Foundation, 9500 Euclid Ave., 
Cleveland, OH 44195. 
*Current address: Department ofSurgery, Catholic University, 
Santiago, Chile. 
Copyright 9 1995 by The Society for Vascular Surgery and 
International Society for Cardiovascular Surgery, North Ameri- 
can Chapter. 
0741-5214/95/$3.00 + 0 24/6/62399 
782 
prosthetic graft infection (IAPGI) is 2.5%, 1 yet 
IAPGI is associated with mortality and amputation 
rates of 17% and 41%, respectively. 1 Therefore, 
although the incidence of lAPGI  is relatively low, the 
frequency with which lower extremity revasculariza- 
tion procedures are performed and the devastating 
consequences a sociated with IAPGI underscore its 
importance. Despite a clear consensus concerning its 
objectives (i.e., control of infection and limb salvage), 
there is an element of controversy regarding the 
optimal management of IAPGI. Some authors have 
advocated excision of  the entire infected graft fol- 
lowed by revascularization with autogenous tissue 
and/or extraanatomic bypass. 24 Others have sug- 
gested local measures without removal of  the graft, S7 
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whereas partial or complete graft removal and in situ 
revascularization with another synthetic graft also 
have been recommended. TM Still others have sug- 
gested early primary amputation. ~2 
To determine the early mortality and morbidity 
rates and the late survival rate for this complication 
and to clarify its management, we have reviewed our 
entire experience with IAPGI, which encompassed 
the last 35 years. 
PATIENTS AND METHODS 
We collected retrospective data from the hospital 
records of 67 consecutive patients who underwent 
some form of surgical treatment for 68 IAPGIs from 
1959 through 1993. Long-term information was 
obtained during subsequent office visits or by a 
telephone canvass of the panents, their immediate 
families, or their local physicians. The end point of 
data collection was defined as death or follow-up 
within 3 months of study closure. Follow'up was 
complete for 57 patients, but the remaining 10 were 
considered lost to follow-up at a median interval of  
66 months (mean, 89 months; range, 3 days to 280 
monthsL Only three patients, however, were lost to 
follow-up within the 4 years after surgical interven- 
tion for their IAPGI. The median follow-up period 
for the entire series was 4 years (mean, 6years; range, 
0 to 28 years). 
All patients had undergone prior leg revascular- 
ization with~ prosthetic material, and both the proxi- 
mal and distal anastomoses o f their grafts had been 
performed below the inguinal igament. The diagno- 
sis of IAPGI was based on conventional criteria in- 
cluding the presence of exposed synthetic material, 
the presence of purulence or a draining sinus contigu- 
ous with the prosthetic graft, or the isolation of mi- 
croorganisms from excised graft material in conjunc- 
tion with pseudoaneurysm formation, anastomotic 
disruption, or adjacent soft tissue sepsis (Szilagyi 
grade 3 infections). 13 Infection of a prosthetic graft 
developed in the contralateral lower extremity of one 
patient 4 years after graft sepsis had resolved in the 
other leg. This episode was defined as a separate 
event, yielding a total of 68 IAPGI in 67 panents. 
Nevertheless, the reappearance of clinical infection at 
the site of previous graft involvement was considered 
to represent a continuation of the original septic pro- 
cess and was classified as recurrent graft sepsis. 
The study group consisted of 53 men and 14 
women, with a mean age of 62 years (median, 62 
years; range, 37 to 91 years). Forty-eight patients 
(72%) were cigarette smokers, 40 (60%) had clinical 
evidence of coronary artery disease, 31 (46%) had 
hypertension, 21 (31%) had diabetes, and 10 (15%) 
were noted to be obese. Forty-nine (72%) of the 
68 infected grafts had been constructed at our 
center, whereas the remaining 19 (28%) had been 
implanted elsewhere. The IAPGIs involved 58 
femoropopliteal grafts (85%), six femoroinfrapop- 
liteal grafts (9%), two common femoral interposi- 
tion grafts (3%), and two femoral endarterectomy 
patches (3%). The synthetic material was pure, 
Dacron in 35 IAPGI (51%), polytetrafluoroethylene 
(PTFE) in 27 (40%), and human umbilical vein in 
four (6%). The remaining two IAI'GIs (3%) in- 
volved composite grafts composed of PTFE and 
human umbilical vein in one case and PTFE and 
Dacron in the other. 
Fifteen (22%) of the IAPGIs occurred in extremi- 
ties that previously had required proximal (aortoil- 
iofemoral) reconstruction, and a total of 22 IAPGIs 
(32%) occurred in grafts that had been implanted 
during vascular reoperations. The initial site of 
infection was the groin in 39 extremities (57%). 
Sixteen IAPGIs (24%) developed in extremities for 
which major amputations had been performed after 
the original bypass procedure but before the onset of 
graft sepsis. Thirteen of these amputations were 
above the knee, whereas the remaining three were 
below the knee. 
At the time of diagnosis of IAPGI, 26 (38%) of 
68 grafts in the entire series were thrombosed, 37 
(55%) were patent, and the patency status of the 
remaining five (7%) could not be determined. The 
grafts were known to be occluded in 14 (88%) of 16 
previously amputated limbs. Within this subgroup, 
one additional graft was known to be patent, but the 
patency status of the remaining raft was undeter- 
mined. 
Because the median age of the study group was 62 
years and because men outnumbered women by a 
factor of more than 3.5 to 1 in the series, the 
cumulative 5-year survival for the normal U.S. male 
population at age 62 years was calculated from U.S. 
census data for comparison purposes. For this 
calculation the life-table method was used. Further- 
more, it was assumed that the U.S. Census Bureau 
follow-up was complete and that the decrease in 
patient population at each year of age reported by the 
census data was caused entirely by the deaths in the 
interval. 14 
Statistical comparisons were made with Fisher's 
two-tailed exact est or with the chi square test when 
appropriate. Cumulative late survival for the study 
group was calculated by use of the Kaplan-Meier 
method, is
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Table I. Summary of available culture results for 59 graft infections ~
Predominant growth Individual bacteria 
per individual IAPGI (n = 59) isolated (n = 86) 
Microorganism No. % No. % 
No growth 1 2 NA NA 
Staphylococcus 34 58 35 41 
aureus 26 44 26 30 
epidermidis 8 14 9 10 
Gram-negative rods 16 27 35 41 
Pseudomonas 7 11 10 12 
Proteus 4 7 7 8 
Escherichia coil 3 5 10 12 
Enterobacter 1 2 4 5 
Serratia 1 2 2 2 
Bacteroides 0 0 1 1 
IOebsiella 0 0 1 1 
Streptococci 4 7 I0 12 
Enterococci 3 5 5 6 
Gram-positive cocci 1 2 1 1 
NA, Not applicable. 
~Culture data unavailable for nine IAPGIs. 
Table II. Surgical management of 68 IAPGIs in 67 patients 
Group Originat graft disposition/surgical management No. % IAPGI 
A Complete removal without in situ graft replacement 40 59 
No revascularization 33 49 
Synthetic extraanatomic bypass graft 2 3 
In situ autogenous 5 7 
B Complete removal with in situ graft replacement 2 3 
In situ homograft 1 1 
In situ dacron graft 1 1 
C Partial removal la  19 
No revascularization 12 18 
Synthetic extraanatomic bypass graft 1 1 
D No removal 13 19 
Local care 12 18 
Pseudoaneurysm uture _11 1 
68 100 Total 
RESULTS 
By definition, all IAPGIs were heralded at least by 
local findings, and 20 (29%) caused systemic mani- 
festations. The most common sign 0fgraft infection 
was drainage from a wound or sinus tract in 50 
IAPGIs (74%), followed by bleeding or pseudoan- 
eurysm formation in 27 (40%), induration or ten- 
derness cach in 23 (34%), and graft exposure in 12 
(18%). The symptoms and physical findings were 
confined to the groin in 39 extremities (57%). One 
additional patient was discovered to have purulent 
material around the prosthetic graft at the time of 
midthigh amputation. Systemic symptoms included 
fever or chills accompanying 18IAPGIs (26%) and 
anorexia accompanying two (3%). The median 
interval between the initial implantation of the 
prosthetic graft and the clinical diagnosis of IAPGI 
was 3 months (mean, 16 years; range, 0 to 187 
months). The median interval since the last proce- 
dure done on the graft, such as thrombectomy, 
revision, or an amputation that transected the graft, 
was 1 month (mean, 6 months; range, 0 to 110 
months). 
Because of the length of the study period, culture 
data were available for only 59 IAPGIs (87%). 
Staphylococcus species was the predominant pathogen 
isolated, either alone or in combination with other 
microorganisms, from 34 (58%) of these 59 infec- 
tions. Multiple organisms were isolated from 22 
infections (37%), yielding a total of 86 documented 
pathogens from the 59 infections (Table I). Although 
microorganisms could not be isolated from one 
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Fig.. 1. Graphic representation of frequency oflAPGI and treatment methods used during each 
decade of study of 68 graft infections in 67patients. 
clinical graft infection, staphylococcus organisms 
represented 41% (35/86) of the individual patho- 
gens. Nine IAPGIs yielded cultures posiuve for 
Staphylococcus epidermidis. Whereas two cultures grew 
S. epidermidis alone, the remaining seven yielded 
multiple organisms, one of which was S. aureus. 
Consequently, in our series, only three of 59 IAPGI 
for which culture data were available (4%) were 
low-virulence infections, caused by either S. epider- 
midis alone or an organism that failed to grow in 
standard culture media. Gram-negative rods ac- 
counted for 41% (35/86) of the isolated organisms 
but were predominant in only 27% (16/59) of the 
available cultures (Table I). 
Four general approaches to the initial surgical 
management are summarized in Table II. Complete 
excision was defined as removal of all of the original 
synthetic graft material, whereas partial excision 
indicates that a segment of the original graft was left 
undisturbed. Because the exact amount of residual 
graft material often could not be determined retro- 
spectively, the excision was classified as partial if any 
of the original graft remained in place. Forty infec- 
tions, representing 59% of the 68 limbs in the entire 
series, were treated by complete removal of the 
original graft with no synthetic replacement in the 
contaminated bed (group A). Two infections (3%) 
were managed with complete removal of the original 
graft and simultaneous in situ revascularization with 
another nonautogenous graft (group B). Thirteen 
infections (19%) were treated by partial removal of 
the original graft, the remaining segment presumably 
being uninfected (group C). Thirteen infections 
(19%) were managed by use of local measures only, 
such as incision and drainage, debridement, and 
dressing changes (group D). In one of these patients 
a pseudoaneurysm was repaired by primary suture of 
the involved anastomosis. None of the original graft 
material was removed initially from group D limbs. 
The frequency of IAPGI relative to the decade of the 
study is summarized in Fig. 1. Twenty-six (38%) of 
the 68 IAPGIs were managed in the most recent 
decade of the study. Total excision was performed for 
77% (20/26) of the IAPGIs in this decade but in only 
48% (20/42) of all prior IAPGIs. 
The results of each method of initial management 
are summarized in Table III. Only five recurrent 
infections (13%) developed after all synthetic mate- 
rial had been excluded from the contaminated field in 
40 IAPGIs (group A), whereas recurrent infections 
occurred in 23 (82%) of the 28 limbs (2 < 0.001) in 
the other three treatment groups. The thirteen 
IAPGIs in grou p D that were treated locally without 
graft resection are of particular interest. Four of these 
(31%) were associated with systemic symptoms of 
sepsis. Six grafts in group D were patent (46%) at the 
time of diagnosis of IAPGI, whereas four were 
occluded (31%) and the patency status of the 
remaining 3 could not be determined. Of the six 
patent grafts, one had developed a pseudoaneurysm 
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Table III. Recurrent graft sepsis and deaths for each treatment group for 68 IAPGIs in 67 patients 
Subsequent operation for sepsis Perioperative deaths 
Excision method Group n (IAGPI) n (Patients) No. % (IAPGI) No. % Patients 
Complete A 40 39 5 13 7 18 
B 2 2 2 100 I 50 
C 13 13 8 62 3 23 
D 13 13 13 100 1 8 
Incomplete B + C + D 28 28 23 8;2 5 18 
Tot~ 68 67 28 41 12 18 
Table IV. Amputation incidence for each treatment group for 68 IAPGIs in 67 patients 
Total (n = 6~ Group A (n = 4~ Group B (n = 2) Group C (n = 1~ Group D (n = 1~ 
AmpumNon No. % No. % No. % No. % No. % 
Prior 16 24 15 38 0 0 1 8 0 0 
Subsequent(s) 23 34 12 30 1 50 5 38 5 38 
Level 
Above-knee (12) (52)* (5) (42) (1) (100) (3) (60) (3) (60) 
Below-knee (10) (43) (6) (50) (0) (0) (2) (40) (2) (40) 
Unknown (1) (5) (1) (8) (0) (0) (0) (0) (0) (0) 
*Numbers in parentheses are subsequent amputations. 
and two others presented with hemorrhage. Nonex- 
cisional treatment was never successful for group D 
limbs, and all of these grafts eventually required 
complete xcision for the control of sepsis. In situ 
revascularization with nonautogenous grafts was 
attempted on only two occasions (group B), but both 
required reoperation for infection. 
This report includes only 10 IAPGIs for which 
standard cultures yielded no organisms (one infec- 
tion) or S. epidermidis either alone (two infections) or 
in combination with other bacteria (seven infec- 
tions), Consequently, only three of the 68 LAPGIs in 
our series (4%) were caused by a low-virulence 
pathogen, which either failed to grow in conven- 
tional culture media or consisted of S. epidermidis 
alone. Infection recurred in one patient who had no 
growth and who was treated with only local mea- 
sures, but infection did not recur in two others who 
had growth of S. epidermidis and were treated with 
complete graft excision. 
Twenty-three xtremities required major amputa- 
tions, including a hip disartictflation i  one patient 
(Table IV). Twenty-three (44%) of the 52 limbs that 
were intact at the time IAPGI was discovered subse- 
quently were amputated, 12 of these above the knee. 
Twenty-one of the 23 amputations were necessary 
within the first year after IAPGI was diagnosed. 
Some type of vascular reconstruction was attempted 
in 10 of the 52 intact limbs. Although only two 
(20%) of these required major amputations, com- 
pared with 19 (45%) of the 42 limbs for which no 
revascularization was performed, this difference did 
not achieve statistical significance (p = 0.174). 
Eleven patients died within 30 days after their 
initial operations for LAPGI. One additional patient 
died of bleeding from a ruptured mycotic femoral 
pseudoaneurysm at the site from which an infected 
graft had been removed 35 days earlier, and this death 
also was considered to represent a related postoper- 
ative event. Therefore the postoperative mortality 
rate was 18% (12/67). Seven (58%) of the 12 early 
deaths were caused by uncontrolled sepsis or second- 
ary hemorrhage (Table V). Two additional patients 
were lost to follow-up in the early postoperative 
interval. There were no fatal complications among 
the 16 patients with prior amputations, compared 
with twelve deaths (24%) within the group of 51 
patients who had intact limbs at the onset of graft 
sepsis (p = 0.056). Fifteen (94%) of the 16 ampu- 
tated limbs initially were treated by complete removal 
of the infected graft, but this approach was taken in 
only 25 (48%) of the 52 intact limbs (p = 0.001). 
The results of treatment methods with respect to 
graft patency at the time of IAPGI discovery are 
summarized in Table VI. Only one IAPGI (3%) 
among 37 patent grafts was associated with prior 
amputation, whereas 14 infections (54%) occurring 
in 26 occluded grafts involved previously amputated 
limbs (p < 0.001). However, incomplete xcision 
was associated with increased rates of reoperation for 
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Table V. Cause of death after surgical treatment of 68 IAPGIs in 67 patients 
Cause No. % 
Early deaths (3-35 days) 
Total 
Late deaths (7 mo-28 yr) 
Total 
Hemorrhage 5 42 
Sepsis/multisystem failure 2 17 
Congestive heart failure 2 17 
Gastrointestinal bleeding 1 8 
Stroke 1 8 
Acute kidney failure __1 8 
12 100 
Unknown 11 38 
Cardiac 10 35 
Cancer 3 10 
Stroke 2 7 
Aortic aneurysm 1 3 
Pneumonia 1 3 
Vasculitis 1 3 
29 100 
Table VI. Summary of treatment results with respect to graft patency at the time of discovery of 
68 IAPGI in 67 patients 
Subsequent operation for sepsis 
Amputation 
Prior Subsequent Perioperative d aths 
Gra~ Excision n n % % % % 
status method (IAPGI) (Patients) No. (IAPGI) No. (IAPGI) No. (IAPGI) No. (Patients) 
Patent Complete 21 21 2 10 1 5 11 52 6 29 
Incomplete 16 16 12 75 O 0 7 44 4 25 
Total 37 37 14 39 1 3 18 49 10 27 
Occluded Complete 17 i6.5 ~ 2 12 13 76 I 6 0 0 
Incomplete 9 __8.5 ~ __8 89 __1 11 3 33 1 12 
Total 26 25 10 38 14 54 4 15 1 4 
Unknown Complete 2 2 1 50 1 50 0 0 1 50 
Incomplete 3 3 3 100 O 0 1 33 O 0 
Total 5 5 4 80 1 20 1 20 1 20 
~One patient had two IAPGIs; one was completely excised and the other incompletely excised. 
sepsis irrespective of graft patency at presentation, 
however (75% vs 10% for patent grafts, p < 0.001; 
89% vs 12% for occluded grafts, p = 0.0002). The 
perioperati~e mortality rate was higher for patients 
presenting with patent grafts (27%) than for those 
with occluded grafts (4%) (p = 0.038). 
The median follow-up interval for the remaining 
53 patients who survived operation was 5 years 
(mean~ 7.5 years; range, 50 days to 28 years). 
Twenty-nine patients died during this period, none 
of persistent sepsis (Table V). Cumulative Kaplan- 
Meier 5- and 10.year survival rates for all 67 patients 
in the entire series were 63% (SE = 6.4%) and 40% 
(SE = 7.4%), respectively. The corresponding actu- 
arial survival rates for the 53 survivors of operation 
were 77% (SE = 6.4%) and 49% (SE = 8.6%), 
respectively (Fig. 2). The comparable 5-year life-table 
survival rate calculated for the normal male U.S. 
population at age 62 years is 89% (SE = 0.11%). 
The corresponding 5-year life-table survival rates 
calculated for survivors of operation (78%) and for 
the entire series (64%) are significantly less (p < 
0.0001 for each comparison) than that of the normal, 
age-matched U.S. male population (89%). 
DISCUSSION 
The optimal management of IAPGI is prob- 
lematic. Early diagnosis, at a time when treatment 
is most likely to be effective, is often difficult. 
Moreover, because the indications for the original 
graft often included limb-threatening ischemia, 
some type of alternative revascularization usually is 
necessary to avoid amputation, if the infected graft 
is not already occluded. As a practical matter, 
however, suitable autogenous conduits rarely are 
available, or they would have been employed uring 
the original revascularization procedure. Treatment 
is further confounded by the variable biologic be- 
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havior of different pathogens that may colonize 
graft infections, ,8,9,11,1618 
Early attempts at nonresectional methods of 
management oflAPGI generally were disappointing. 
Recurrent infections with systemic sepsis, pseudoan- 
eurysm formation, and anastomotic hemorrhage 
were common and could be encountered ven late in 
the postoperative p riod.* Consequently, excision of 
the prosthetic material and either revascularization 
with autogenous tissue or the placement of a new 
synthetic graft in clean anatomic planes is now the 
preferred surgical approach at many centers. 24,21,22 
Nevertheless, the mortality and morbidity rates 
associated with IAPGI have remained formidable 
despite aggressive therapy.  12,19,2~ For  this reason the 
fact that some authors have described successful 
results in selected patients with IAPGI without 
complete removal of the involved graft has attracted 
considerable attention. 6,811,1316,2~ Many of these 
reports comprise relatively small series of patients 
with limited follow-up; yet they appear to demon- 
strate that IAPGI occasionally may be confined to a 
glycoprotein biofilm coating the synthetic material 
*References 2, 3, 5, 12, 13, 19, and 20. 
that can be excised and successfully replaced with a 
new prosthetic graft in the same bed. 8,n,14,1s'17 This 
is an important concept, but it may apply only to 
infections caused by organisms having intrinsically 
low virulence (e.g., S. epidermidis). 
The increased rate of recurrent infection associ- 
ated with incomplete graft excision in our series may 
reflect not only the advanced stages of graft infection 
among our patients at the time of treatment but also 
the practical difficulty in making the diagnosis of 
limited, nonvirulent IAPGI suitable for conservative 
treatment in the usual clinical setting. Our report 
concerns infections that were well established atthe 
time of their initial treatment. Only three IAPGIs 
(4%) in our experience involved apparently low- 
virulence organisms. Two resolved after complete 
graft excision, but one recurred espite local care. 
Although the predominant pathogen in this series 
was Staphylococcus species, infections caused by gram- 
negative rods also were quite common and often 
occurred in the presence of mixed flora. Gram- 
negative IAPGIs are recognized to be more invasive 
than is the case with biofilm irffections, 5 17 and 
because the interval from graft implantation to the 
diagnosis of IAPGI was only 3 months, the infections 
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in our series were comparatively virulent. Further- 
more, deep infection involving the arterial wall has 
been associated with an increased incidence of suture 
line disruption, and its undetected presence may have 
been a factor in the failure of  incomplete excisional 
treatment in some of our patients. 922 
Conceding the liabilities of  a retrospective study, 
we believe our experience with established IAPGI 
generally indicates that aggressive treatment provides 
better results, at least until more reliable diagnostic 
methods are available. The incidence of recurrent 
infection was significantly lower when complete graft 
excision was performed. The early postoperative 
mortality rate was 18%, but 58% of these deaths were 
related to uncontrolled sepsis. No perioperative 
deaths occurred among patients who presented with 
prior amputations, yet the early mortality rate was 
24% for those patients who had intact limbs at the 
time they were discovered to have IAPGI This 
difference may be related to the fact that 94% of the 
IAPGIs that occurred in amputated extremities were 
treated by complete graft excision, compared with 
about half of IAPGIs in the intact limbs. The 5-year 
life expectancy for survivors of  operation was less 
than that of an age-matched, normal U.S. male 
population, suggesting that their long-term survival 
is probably compromised by other factors associated 
with systemic atherosclerosis even when the septic 
process is controlled. IAPGI is associated with a 
significant risk for limb loss, however. Nearly half 
(40%/ of the intact limbs with IAPGI in our series 
required amputations within 1 year of  diagnosis, and 
more than half of these were above the knee. 
Nevertheless, revascularization of the ischemic ex- 
tremity at the time of treatment for IAPGI was 
rewarded with twice the limb salvage rate as was the 
case when revascularization either was not attempted 
or was not feasible. 
Mthough incomplete graft excision may be ac- 
ceptable for some carefully selected patients with 
IAPGI, we advise caution in its application. In 
addition to specific antibiotic therapy, we conclude 
that complete removal of all involved prosthetic 
material with adequate debridement of infected 
tissues is usually necessary for the management of  
established IAPGI. If the limb is severely ischemic 
after graft removal, autogenous revascularization 
should be attempted if at all possible. In the absence 
of autogenous material, extraanatomic bypass with 
another synthetic graft may be considered; but it 
becomes increasingly difficult if the original infected 
graft already extends below the knee. Incomplete 
graft removal has been only infrequently successful in 
our experience, and we believe it requires careful 
long-term surveillance for recurrent infection when- 
ever it is attempted. 
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DISCUSSION 
Dr. Jonathan B. Towne (Milwaukee, Wis.). This 
paper demonstrates the high morbidity and mortality rates 
associated with lower limb graft infections. It appears to me 
that the study group actually represents three different 
groups of graft infections. 
The first is early infections, which I define as occurring 
less than 3 months after the implantation of the graft and 
which are often, in my experience, related to wound healing 
complications in which coagulase-positive staphylococcus 
is a principal organism. Because in this series the mean time 
from insertion of the graft to occurrence of infection was 
3 months, I suspect many of these patients fall into this 
group. 
The second group is what I would call late infections. 
These infections usually are defined as occurring more than 
3 months after the insertion of the prosthesis and often 
months and years later in the follow-up period. These are 
often graft biofilm infections caused by coagulase-negative 
staphlococci. 
The third group is an interesting roup. These infec- 
tions occur in previously occluded grafts in limbs that had 
undergone a previous major amputation. In this group the 
question is what factor did the infection play in the overall 
scheme of things? I would like to know how many of those 
occluded grafts that became secondarily infected were 
related to wound healing complications that occurred at the 
time of the major amputation. It is our policy to do subtotal 
graft excisions in any patient on whom we do a major 
amputation. We dissect out the groin but go a little distal 
to the groin and remove the remainder of the graft. 
The bottom line is to get some sense of the Cleveland 
Clinic's algorithm for treating these grafts. If you look at 
the data in this paper, only seven of the 40 patients who had 
complete xcision had some sort of extraanatomic bypass. 
Because the amputation and mortality rates were incredibly 
high, we have to ask ourselves what should you do? When 
do you do a bypass? What do you bypass? And how often 
do you do a primary major amputation? Because the 
incidence of amputation i  patients with an intact limb at 
the time of the infection was 44% and because the mortality 
rate was 18% in approximately half of these above-knee 
amputations, can you determine whether the surgical 
results have improved over the 34-year span of this study. 
For example, in the last 5 years, have the results improved, 
and to what do you attribute that improvement? 
Dr. Patrick J. O'Hara. I have tried to determine why 
we cannot successfully treat grafts in situ or replace them in 
situ very often, because I believe it certainly would be a 
much easier thing to do. Part of our problem might be in 
correctly diagnosing low virulence infections. Considering 
the algorithm question first, among the grafts that were 
reported, the diagnosis of infection was very clear. Some 
grafts that were more mildly infected may have been 
missed, but the ones that were clearly infected and that had 
advanced infections at presentation were unlikely to have 
been helped without taking out the graft. As a result, 
usually we obtained arteriography and planned revascular- 
ization with autogenous or extraanatomic tissue ahead of 
time. Often the remaining options were very limited, which 
perhaps might account for our amputation rate. The 40% 
figure for amputation seems to be fairly constant, at least in 
reports of infrainguinal graft infection. 
I tried to analyze the data to determine whether our 
resuks have improved over time. However, this is a 
retrospective study. The study interval-35 years-was 
very long, and the numbers, although substantial, are still 
small. The result is that we could not demonstrate a 
difference. I suspect the high morbidity and mortality rates 
reflect he small number of patients with serious problems. 
Concerning the subgroup of patients with infections 
related to previous amputations, most of these probably 
were secondarily infected at the time of amputation. 
Because 52 of the 68 patients had previously intact limbs, 
the amputation group is a relatively small subset. 
Dr. Bhagwan Satiani (Columbus, Ohio). I notice that 
you also included the exposed grafts. I wonder if you would 
separate the treatments by exposed grafts versus infected 
grafts. Exposed grafts are usually infected early on, when 
wound separations occur, typically in obese patients with 
diabetes. Would you recommend leaving such grafts and 
treating them with local coverage (versus an infected graft 
with gross purulence and positive cultures, etc.)? 
Dr. O'Hara. We have done what you have proposed 
only rarely. When we have tried to rotate flaps over such 
grafts, they have often become infected. I believe our study 
should be viewed as a cautionary note in such situations. I 
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also think that, if this is attempted, the patient deserves very 
close long-term follow-up because recurrence of infection 
is not uncommon in such situations. 
Dr. Kevin James (Cincinnati, Ohio). Some recent 
reports have documented good results with rotational 
muscle flaps and long-term administration of antibiotics. 
Was muscle flap coverage and prolonged antibiotic therapy 
part of your local treatment, and if so, was your choice of 
treatment based on the type of infection, that is, gram- 
negative versus gram-positive infections? 
Dr. O'Hara.  Again, we tried your method over a long 
period of time, in a relatively few patients. I think 13 were 
in one group and two were in another group. We were 
unsuccessful, and unable to figure out why. Part of the 
reason may be that we saw a high incidence of gram- 
negative infections and staphyloccal infections, and were 
unable to make the diagnosis of low virulence infections 
well or early enough to discern which grafts we could treat 
in sire. 
Dr, Mark Adams (Milwaukee, Wis.). Have you ever 
considered using fresh cadaveric artery to replace segments 
that are infected or prostheses that yon remove? It is not 
that difficult to get these days, and I do not think 
immunosuppression is necessary because the short dura- 
tion of time that you would need it, such as to substitute 
for autogenous vessel. 
Dr. O'Hara.  No we have not, and I appreciate the 
recommendation. 
